CXCL10 and tuberculosis: To assess whether IP-10 can be used as a biomarker for monitoring TB treatment, we evaluated the IP-10 level in the urine of 18 patients, 9 of whom were tested 2 months after AFB smear sputum reversion and 9 of whom were cured of TB (Figure 3, Table 1).